We show that several analogs of thyrotropin-releasing hormone (TRH) are more efficacious agonists at TRH receptors R1 and R2 than TRH itself. The apparent efficacies of the analogs were inversely related to their potencies and were independent of the nature of the modifications in TRH structure. In studies in intact cells, we showed that the differences in apparent efficacies were not due to differences in G-protein coupling, receptor desensitization, or recycling. Moreover, the differences in efficacies persisted in experiments using accessory protein-free membranes. We conclude that the efficacy differences of TRH analogs originated from the enhanced ability of TRH-R complexed to the low affinity agonists to directly activate G-protein(s), and not by a modulation of the activity of accessory proteins, and propose possible mechanisms for this phenomenon.Thyrotropin-releasing hormone (TRH) 2 receptors (TRH-Rs) are members of the rhodopsin-like family (family A) of G-protein coupled receptors. TRH-Rs couple primarily to the G q/11 subfamily of G-proteins and mediate the intracellular release of Ca 2ϩ through the activation of the inositol phosphate (IP) pathway (1). There are two subtypes of TRH-Rs, TRH-R1 and TRH-R2, that share about 50% sequence homology (2, 3). The physiological significance of the existence of two kinds of TRH-Rs remains unknown. TRH-R1 and TRH-R2 exhibit subtle functional differences varying in the level of stimulated and basal signaling, the rate of internalization, and the ability to couple to G-proteins other than G q/11 (2-4). The ligand binding affinities of TRH analogs to the two receptors, however, are very similar (2). TRH is the natural agonist for both TRH-Rs, and numerous synthetic analogs of TRH have been shown to stimulate both receptors (2). Except for substitution of His by 1-methyl-His, all substitutions within TRH result in analogs with reduced affinities, but all are agonists.The nature of the molecular changes that are responsible for TRH-R activation remain mainly unknown. The absence of a working hypothesis for the mechanism of TRH-R activation precludes the use of a rational approach to develop new agonists for these receptors. Therefore, study of structure-activity relationships of the known TRH-R1/R2 agonists may contribute to a better understanding of the structural basis of the efficacies of TRH-R-agonist complexes, which is necessary for development of more efficient (specific) modulators of TRH-R activity. In this work, we demonstrate a unique pharmacological profile of a series of TRH analogs in which affinities (potencies) of the compounds are related in an inverse mode to their ability to activate TRH-R1/R2. A corollary of these observations is that certain TRH analogs act as "superagonists" for TRH-R1/R2. We propose possible mechanisms for this effect.